{
  "pages": [
    {
      "page_number": 1,
      "image_path": "output/novartis-sample_images/page_001.png",
      "snippets": [
        {
          "title": "Neuroscience Pipeline Focus",
          "content": "Neuroscience pipeline focuses on multiple sclerosis, neuromuscular and neurodegenerative diseases.",
          "enriched_content": "Neuroscience {therapeutic_area} pipeline focuses on multiple sclerosis {disease}, neuromuscular {therapeutic_area} and neurodegenerative diseases {therapeutic_area}.",
          "tag_mapped_tables": [
            "diseases",
            "therapeutic_modalities"
          ],
          "relevant_tables": [
            [
              "therapeutic_modalities",
              0.33075067371871963
            ]
          ]
        },
        {
          "title": "Neuroscience Strategy: Disease Areas, Assets, and Platforms",
          "content": "Disease areas (selected):\n\u2022 Multiple Sclerosis\n\u2022 Neuromuscular (Spinal Muscular Atrophy, others)\n\u2022 Neurodegeneration (Alzheimer's, Parkinson's, Huntington's)\nAnchor assets:\n\u2022 Kesimpta\n\u2022 Zolgensma\u00ae\nAdvanced platform capabilities:\n\u2022 Gene therapy\n\u2022 xRNA\n\u2022 Immune reset",
          "enriched_content": "Disease areas (selected):\n\u2022 Multiple Sclerosis {disease}\n\u2022 Neuromuscular {therapeutic_area} (Spinal Muscular Atrophy {disease}, others)\n\u2022 Neurodegeneration {therapeutic_area} (Alzheimer's {disease}, Parkinson's {disease}, Huntington's {disease})\nAnchor assets:\n\u2022 Kesimpta {drug}\n\u2022 Zolgensma\u00ae {drug}\nAdvanced platform capabilities:\n\u2022 Gene therapy {modality}\n\u2022 xRNA {modality}\n\u2022 Immune reset {modality}",
          "tag_mapped_tables": [
            "drugs",
            "diseases",
            "therapeutic_modalities"
          ],
          "relevant_tables": [
            [
              "therapeutic_modalities",
              0.3930590944327677
            ],
            [
              "drug_modalities",
              0.3829310067287697
            ],
            [
              "transaction_assets",
              0.3763945494091741
            ],
            [
              "drug_development_roles",
              0.375033758232057
            ],
            [
              "research_program_modalities",
              0.3681812567591494
            ],
            [
              "diseases",
              0.3680657334104785
            ],
            [
              "combination_indication_specifications",
              0.3675184015835097
            ],
            [
              "market_catalysts",
              0.3674185308064306
            ],
            [
              "indication_specifications",
              0.3661610311877753
            ],
            [
              "research_program_indications",
              0.35620168673885944
            ],
            [
              "drug_targets",
              0.3511876709497479
            ],
            [
              "market_access_status",
              0.3467630748681223
            ],
            [
              "drugs",
              0.34259084850399657
            ],
            [
              "regulatory_approvals",
              0.34224846544064735
            ],
            [
              "regulatory_review_milestones",
              0.3413267343139346
            ],
            [
              "drug_market_forecasts",
              0.33871468006252714
            ],
            [
              "drug_market_positioning",
              0.33663579093938995
            ],
            [
              "regimens",
              0.3336179906722809
            ],
            [
              "drug_brands",
              0.3331360295739008
            ],
            [
              "drug_combinations",
              0.33183077847910647
            ],
            [
              "clinical_trial_indications",
              0.33044194025381557
            ],
            [
              "molecular_targets",
              0.3281783032837879
            ],
            [
              "drug_trial_details",
              0.3261060898675487
            ],
            [
              "market_sizing",
              0.3250249104496773
            ],
            [
              "regulatory_exclusivity",
              0.32489782625014774
            ],
            [
              "disease_epidemiology",
              0.32451104082932597
            ],
            [
              "research_programs",
              0.32440337176525397
            ],
            [
              "competitive_landscape",
              0.3229804004801993
            ],
            [
              "partnership_details",
              0.32280994736109564
            ],
            [
              "regimen_safety_comparisons",
              0.3196580179166491
            ],
            [
              "combination_efficacy_comparisons",
              0.3163284009832494
            ],
            [
              "regimen_efficacy_comparisons",
              0.31497338481112375
            ],
            [
              "regimen_components",
              0.31096885858952217
            ],
            [
              "regulatory_submissions",
              0.31094102631401577
            ],
            [
              "regulatory_review_pathways",
              0.3108388265811968
            ],
            [
              "regulatory_application_types",
              0.31010513131708095
            ],
            [
              "clinical_trial_sites",
              0.3088690183030417
            ],
            [
              "regulatory_communications",
              0.30868075921683086
            ],
            [
              "standard_of_care",
              0.3080017909362308
            ],
            [
              "clinical_trials",
              0.30653837893058156
            ],
            [
              "clinical_trial_drugs",
              0.305700486493753
            ],
            [
              "drug_classes",
              0.3054140731263769
            ],
            [
              "combination_safety_comparisons",
              0.30419276881765983
            ],
            [
              "clinical_trial_arms",
              0.3023028822033881
            ],
            [
              "drug_combination_components",
              0.3019561995398958
            ]
          ]
        },
        {
          "title": "Neuroscience Pipeline Details",
          "content": "Selected projects (indication) | Pre-clinical | Phase I | Phase II | Phase III | Registration | Next milestone/status\nRemibrutinib (MS) |  |  |  | Phase III |  | Readout 2026 [MS/Neuroimmunology]\nIptacopan (gMG) |  |  |  | Phase III |  | Readout 2027 [MS/Neuroimmunology]\nYTB323 (RMS)\u00b9 |  |  | Phase II |  |  | Trial recruiting [MS/Neuroimmunology]\nYTB323 (PPMS)\u00b9 |  |  | Phase II |  |  | Trial recruiting [MS/Neuroimmunology]\nYTB323 (gMG)\u00b9 |  |  | Phase II |  |  | Trial recruiting [MS/Neuroimmunology]\nOAV101 (SMA IT) |  |  |  |  | Registration | Submission in 2025 [Neuromuscular]\nKATE (FSHD, DM1) | Pre-clinical |  |  |  |  | Lead optimization/Discovery [Neuromuscular]\nEDK060 (CMT1A) | Pre-clinical |  |  |  |  | IND in preparation [Neuromuscular]\nPTC518 (HD)\u00b2 |  | Phase I |  |  |  | Trial ongoing [Neurodegenerative]\nNIO752 (tau ASO) (AD, PSP) |  | Phase I |  |  |  | First readout 2025 [Neurodegenerative]\nVHB937 (TREM2) (ALS) |  | Phase I |  |  |  | Trial recruiting [Neurodegenerative]\nVHB937 (AD) |  | Phase I |  |  |  | Starting PhII in 2025\u00b3 [Neurodegenerative]\nDisease area legend: MS/Neuroimmunology (Dark Blue), Neuromuscular (Medium Blue), Neurodegenerative (Grey).",
          "enriched_content": "```\nSelected projects (indication) | Pre-clinical {development_stage} | Phase I {development_stage} | Phase II {development_stage} | Phase III {development_stage} | Registration {development_stage} | Next milestone/status\nRemibrutinib {drug} (MS {disease}) |  |  |  | Phase III {development_stage} |  | Readout {clinical_milestone} 2026 {timeline} [MS/Neuroimmunology {therapeutic_area}]\nIptacopan {drug} (gMG {disease}) |  |  |  | Phase III {development_stage} |  | Readout {clinical_milestone} 2027 {timeline} [MS/Neuroimmunology {therapeutic_area}]\nYTB323 {drug} (RMS {disease})\u00b9 |  |  | Phase II {development_stage} |  |  | Trial recruiting {clinical_milestone} [MS/Neuroimmunology {therapeutic_area}]\nYTB323 {drug} (PPMS {disease})\u00b9 |  |  | Phase II {development_stage} |  |  | Trial recruiting {clinical_milestone} [MS/Neuroimmunology {therapeutic_area}]\nYTB323 {drug} (gMG {disease})\u00b9 |  |  | Phase II {development_stage} |  |  | Trial recruiting {clinical_milestone} [MS/Neuroimmunology {therapeutic_area}]\nOAV101 {drug} (SMA IT {disease}) |  |  |  |  | Registration {development_stage} | Submission {clinical_milestone} in 2025 {timeline} [Neuromuscular {therapeutic_area}]\nKATE (FSHD {disease}, DM1 {disease}) | Pre-clinical {development_stage} |  |  |  |  | Lead optimization/Discovery {development_stage} [Neuromuscular {therapeutic_area}]\nEDK060 {drug} (CMT1A {disease}) | Pre-clinical {development_stage} |  |  |  |  | IND in preparation {clinical_milestone} [Neuromuscular {therapeutic_area}]\nPTC518 {drug} (HD {disease})\u00b2 |  | Phase I {development_stage} |  |  |  | Trial ongoing {clinical_milestone} [Neurodegenerative {therapeutic_area}]\nNIO752 {drug} (tau {target} ASO {modality}) (AD {disease}, PSP {disease}) |  | Phase I {development_stage} |  |  |  | First readout {clinical_milestone} 2025 {timeline} [Neurodegenerative {therapeutic_area}]\nVHB937 {drug} (TREM2 {target}) (ALS {disease}) |  | Phase I {development_stage} |  |  |  | Trial recruiting {clinical_milestone} [Neurodegenerative {therapeutic_area}]\nVHB937 {drug} (AD {disease}) |  | Phase I {development_stage} |  |  |  | Starting PhII {clinical_milestone} in 2025 {timeline}\u00b3 [Neurodegenerative {therapeutic_area}]\nDisease area legend: MS/Neuroimmunology {therapeutic_area} (Dark Blue), Neuromuscular {therapeutic_area} (Medium Blue), Neurodegenerative {therapeutic_area} (Grey).\n```",
          "tag_mapped_tables": [
            "diseases",
            "therapeutic_modalities",
            "entity_milestones",
            "molecular_targets",
            "drugs",
            "program_terminations",
            "indication_specifications"
          ],
          "relevant_tables": [
            [
              "clinical_trials",
              0.5326397110389514
            ],
            [
              "drug_development_roles",
              0.5191298414246897
            ],
            [
              "regulatory_review_milestones",
              0.5133914868426713
            ],
            [
              "clinical_trial_indications",
              0.4949809865392069
            ],
            [
              "market_catalysts",
              0.4911051265699635
            ],
            [
              "clinical_trial_drugs",
              0.48403218752874827
            ],
            [
              "combination_indication_specifications",
              0.48139125499766183
            ],
            [
              "research_program_indications",
              0.4773155333476953
            ],
            [
              "indication_specifications",
              0.4769540740463623
            ],
            [
              "clinical_trial_sites",
              0.47664843950402547
            ],
            [
              "regulatory_approvals",
              0.47572229913842917
            ],
            [
              "drug_trial_details",
              0.4738100286837338
            ],
            [
              "trial_enrollment_tracking",
              0.4714224527967935
            ],
            [
              "drugs",
              0.4706564932502064
            ],
            [
              "research_program_modalities",
              0.46872996776603226
            ],
            [
              "regulatory_review_pathways",
              0.46749782938523005
            ],
            [
              "research_programs",
              0.4671852163507506
            ],
            [
              "drug_market_forecasts",
              0.4665997119212601
            ],
            [
              "therapeutic_modalities",
              0.46482556713296974
            ],
            [
              "drug_targets",
              0.46475800882466417
            ],
            [
              "clinical_data_points",
              0.46460511018538525
            ],
            [
              "clinical_trial_geographies",
              0.4637157075447488
            ],
            [
              "drug_modalities",
              0.457447480240667
            ],
            [
              "regulatory_communications",
              0.4545077683763403
            ],
            [
              "drug_combinations",
              0.45388101404538383
            ],
            [
              "standard_of_care",
              0.45378354018802386
            ],
            [
              "clinical_trial_design",
              0.4533905610301984
            ],
            [
              "regulatory_exclusivity",
              0.4525102721684326
            ],
            [
              "regulatory_submissions",
              0.4518351338600635
            ],
            [
              "drug_brands",
              0.4505920147048256
            ],
            [
              "clinical_trial_arms",
              0.4500743827343763
            ],
            [
              "clinical_trial_registries",
              0.4499826246353094
            ],
            [
              "regimen_safety_comparisons",
              0.44967808651728547
            ],
            [
              "regulatory_designations",
              0.44914716378341973
            ],
            [
              "market_access_status",
              0.44854790186663107
            ],
            [
              "drug_market_positioning",
              0.4430506511928103
            ],
            [
              "combination_safety_comparisons",
              0.44137505284065526
            ],
            [
              "regulatory_designation_types",
              0.4374994653261142
            ],
            [
              "competitive_landscape",
              0.4374647148758469
            ],
            [
              "combination_efficacy_comparisons",
              0.43726422267357723
            ],
            [
              "regimen_efficacy_comparisons",
              0.43703853000316534
            ],
            [
              "market_sizing",
              0.43547032388905477
            ],
            [
              "regimens",
              0.43416195477842845
            ],
            [
              "milestone_types",
              0.43201696327758543
            ],
            [
              "disease_epidemiology",
              0.4303477903849854
            ],
            [
              "partnership_details",
              0.42977118314343493
            ],
            [
              "trial_geography_regulatory_status",
              0.42925033551907954
            ],
            [
              "program_terminations",
              0.4285372429652137
            ],
            [
              "molecular_targets",
              0.4284983284591499
            ],
            [
              "clinical_trial_publication_details",
              0.42796540866558375
            ]
          ]
        },
        {
          "title": "Footnotes",
          "content": "1. Phase I / II. \n2. Novartis has signed an exclusive global license agreement with PTC Therapeutics. This transaction is subject to customary closing conditions, including regulatory clearance. \n3. Direct to Phase II.",
          "enriched_content": "1. Phase I / II {development_stage}.\n2. Novartis {company} has signed an exclusive global {geographic_region} license agreement with PTC Therapeutics {company}. This transaction is subject to customary closing conditions, including regulatory clearance {clinical_milestone}.\n3. Direct to Phase II {development_stage}.",
          "tag_mapped_tables": [
            "entity_milestones",
            "companies",
            "drugs",
            "geographies",
            "program_terminations",
            "indication_specifications"
          ],
          "relevant_tables": [
            [
              "clinical_trials",
              0.3825142565354956
            ],
            [
              "drug_development_roles",
              0.36952161794188426
            ],
            [
              "clinical_trial_indications",
              0.36113305273239266
            ],
            [
              "regulatory_approvals",
              0.3390622897980419
            ],
            [
              "clinical_trial_geographies",
              0.3330705482565675
            ],
            [
              "clinical_trial_sites",
              0.32540806540617423
            ],
            [
              "clinical_trial_drugs",
              0.3238960561189893
            ],
            [
              "regulatory_exclusivity",
              0.3170599066569061
            ],
            [
              "deal_stages",
              0.3158867458900254
            ],
            [
              "partnership_details",
              0.3134721502407899
            ],
            [
              "licensing_details",
              0.31069144561388984
            ],
            [
              "combination_indication_specifications",
              0.3104717922024205
            ],
            [
              "research_programs",
              0.30962034748860057
            ],
            [
              "market_access_status",
              0.30856970508890724
            ],
            [
              "market_catalysts",
              0.3072167265300684
            ],
            [
              "regulatory_review_milestones",
              0.30529828067637693
            ],
            [
              "commercial_rights",
              0.30412172414083705
            ],
            [
              "indication_specifications",
              0.301752328192374
            ],
            [
              "clinical_trial_design",
              0.30174058327995706
            ],
            [
              "drug_combinations",
              0.3000067349206052
            ]
          ]
        },
        {
          "title": "Document Context",
          "content": "NOVARTIS Reimagining Medicine\nNovartis growth story | January 14, 2025 | 23",
          "enriched_content": "NOVARTIS {company} Reimagining Medicine\nNovartis {company} growth story | January 14, 2025 {timeline} | 23",
          "tag_mapped_tables": [
            "companies"
          ],
          "relevant_tables": [
            [
              "drug_market_forecasts",
              0.3201118992633821
            ],
            [
              "drug_development_roles",
              0.3147638139038045
            ],
            [
              "market_catalysts",
              0.3097037756938357
            ]
          ]
        }
      ]
    }
  ]
}